MET and non-small cell lung carcinoma: Capmatinib (Tabrecta®, Novartis Pharma GmbH, Basel, Switzerland) and tepotinib (Tepmetko®, Merck KGaA, Darmstadt, Germany) have been approved for the treatment of patients with advanced non-small cell lung carcinoma (NSCLC) and MET exon 14 skipping mutation who are undergoing systemic therapy after platinum-based chemotherapy or require treatment using immunotherapy.